184 related articles for article (PubMed ID: 24682667)
1. Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy.
Andrabi R; Makhdoomi MA; Kumar R; Bala M; Parray H; Gupta A; Kotnala A; Thirumurthy V; Luthra K
J Clin Immunol; 2014 May; 34(4):504-13. PubMed ID: 24682667
[TBL] [Abstract][Full Text] [Related]
2. Evolution of cross-neutralizing antibodies and mapping epitope specificity in plasma of chronic HIV-1-infected antiretroviral therapy-naïve children from India.
Makhdoomi MA; Khan L; Kumar S; Aggarwal H; Singh R; Lodha R; Singla M; Das BK; Kabra SK; Luthra K
J Gen Virol; 2017 Jul; 98(7):1879-1891. PubMed ID: 28696188
[TBL] [Abstract][Full Text] [Related]
3. Detection of Neutralizing Antibodies in HIV-1 Patients on Antiretroviral Treatment for Over Ten Years.
Cao W; Wang X; Li B; Lin L; Du Z; Zhao H; Zhang Y; Xu Z; Qiao Y
Clin Lab; 2019 Jul; 65(7):. PubMed ID: 31307159
[TBL] [Abstract][Full Text] [Related]
4. Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk.
Martinez DR; Vandergrift N; Douglas AO; McGuire E; Bainbridge J; Nicely NI; Montefiori DC; Tomaras GD; Fouda GG; Permar SR
J Virol; 2017 May; 91(9):. PubMed ID: 28202762
[TBL] [Abstract][Full Text] [Related]
5. Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy.
Hu X; Hong K; Zhao C; Zheng Y; Ma L; Ruan Y; Gao H; Greene K; Sarzotti-Kelsoe M; Montefiori DC; Shao Y
J Gen Virol; 2012 Oct; 93(Pt 10):2267-2278. PubMed ID: 22791603
[TBL] [Abstract][Full Text] [Related]
6. Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India.
Andrabi R; Bala M; Kumar R; Wig N; Hazarika A; Luthra K
PLoS One; 2012; 7(8):e43704. PubMed ID: 22952740
[TBL] [Abstract][Full Text] [Related]
7. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.
Auewarakul P; Louisirirotchanakul S; Sutthent R; Taechowisan T; Kanoksinsombat C; Wasi C
Viral Immunol; 1996; 9(3):175-85. PubMed ID: 8890476
[TBL] [Abstract][Full Text] [Related]
8. Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia.
Medina-Ramírez M; Sánchez-Merino V; Sánchez-Palomino S; Merino-Mansilla A; Ferreira CB; Pérez I; González N; Alvarez A; Alcocer-González JM; García F; Gatell JM; Alcamí J; Yuste E
J Virol; 2011 Jun; 85(12):5804-13. PubMed ID: 21471239
[TBL] [Abstract][Full Text] [Related]
9. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
[TBL] [Abstract][Full Text] [Related]
10. Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma.
Sajadi MM; Lewis GK; Seaman MS; Guan Y; Redfield RR; DeVico AL
J Virol; 2012 May; 86(9):5014-25. PubMed ID: 22379105
[TBL] [Abstract][Full Text] [Related]
11. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
12. Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.
Andrabi R; Kumar R; Bala M; Nair A; Biswas A; Wig N; Kumar P; Pal R; Sinha S; Luthra K
Virol J; 2012 Sep; 9():196. PubMed ID: 22971578
[TBL] [Abstract][Full Text] [Related]
13. Intrasubtype B HIV-1 Superinfection Correlates with Delayed Neutralizing Antibody Response.
Wagner GA; Landais E; Caballero G; Phung P; Kosakovsky Pond SL; Poignard P; Richman DD; Little SJ; Smith DM
J Virol; 2017 Sep; 91(17):. PubMed ID: 28615205
[TBL] [Abstract][Full Text] [Related]
14. Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.
Ruppach H; Nara P; Raudonat I; Elanjikal Z; Rübsamen-Waigmann H; Dietrich U
J Virol; 2000 Jun; 74(12):5403-11. PubMed ID: 10823844
[TBL] [Abstract][Full Text] [Related]
15. B cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 T cell count, viral load and humoral immune responses.
Oballah P; Flach B; Eller LA; Eller MA; Ouma B; de Souza M; Kibuuka HN; Wabwire-Mangen F; Brown BK; Michael NL; Robb ML; Montefiori D; Polonis VR
PLoS One; 2011; 6(8):e22653. PubMed ID: 21886768
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study.
Gach JS; Achenbach CJ; Chromikova V; Berzins B; Lambert N; Landucci G; Forthal DN; Katlama C; Jung BH; Murphy RL
PLoS One; 2014; 9(1):e85371. PubMed ID: 24454852
[TBL] [Abstract][Full Text] [Related]
17. Neutralization potential of the plasma of HIV-1 infected Indian patients in the context of anti-V3 antibody content and antiretroviral therapy. [corrected].
Choudhary AK; Andrabi R; Prakash SS; Kumar R; Choudhury SD; Wig N; Biswas A; Hazarika A; Luthra K
J Microbiol; 2012 Feb; 50(1):149-54. PubMed ID: 22367950
[TBL] [Abstract][Full Text] [Related]
18. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
[TBL] [Abstract][Full Text] [Related]
19. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection.
Gray ES; Madiga MC; Hermanus T; Moore PL; Wibmer CK; Tumba NL; Werner L; Mlisana K; Sibeko S; Williamson C; Abdool Karim SS; Morris L;
J Virol; 2011 May; 85(10):4828-40. PubMed ID: 21389135
[TBL] [Abstract][Full Text] [Related]
20. Antibodies that cross-neutralize the tier-2 pseudoviruses are produced in antiretroviral-naïve HIV-1-infected children from northern India.
Prakash SS; Andrabi R; Kumar R; Lodha R; Kabra SK; Vajpayee M; Luthra K
Arch Virol; 2012 Sep; 157(9):1797-801. PubMed ID: 22674340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
